Turgay Saritas, MD, PhD
@turgaysaritas.bsky.social
University Hospital Aachen, Germany. Nephrologist, Scientist, Intensivist, focus on kidney remodeling and acute kidney injury.
Our (European Renal Association AKI Working Group) comment on the DEFENDER RCT: academic.oup.com/ndt/advance-...
SGLT2 inhibitors in critically ill patients are safe but do not reduce mortality or length of stay in the hospital. RCTs testing SGLT2i for AKI prevention and treatment are needed.
SGLT2 inhibitors in critically ill patients are safe but do not reduce mortality or length of stay in the hospital. RCTs testing SGLT2i for AKI prevention and treatment are needed.
DEFENDER Trial: Dapagliflozin for Critically Ill Patients with Acute Organ Dysfunction -Implications for clinicians
Jolanta Malyszko, the ERAKI Working group of the European Renal Association, Sophie De Seigneux, the ERAKI Working group of the European Renal Association,
academic.oup.com
January 18, 2025 at 7:12 PM
Our (European Renal Association AKI Working Group) comment on the DEFENDER RCT: academic.oup.com/ndt/advance-...
SGLT2 inhibitors in critically ill patients are safe but do not reduce mortality or length of stay in the hospital. RCTs testing SGLT2i for AKI prevention and treatment are needed.
SGLT2 inhibitors in critically ill patients are safe but do not reduce mortality or length of stay in the hospital. RCTs testing SGLT2i for AKI prevention and treatment are needed.